
<img src="https://www.gustaveroussy.fr/sites/all/themes/gustave_roussy/logo.png" alt="logo GR">
<img src="https://www.inserm.fr/themes/inserm/logo.png" alt="logo INSERM" width="200px">
<img src="https://www.ligue-cancer.net/sites/all/themes/ligue/logo.png" alt="logo LCC">
<img src="https://hal.archives-ouvertes.fr/UNIV-PARIS-SACLAY/public/logo_UP_saclay_final.png" alt="logo UPSC" width="150px">

Oncostat is a research team of the Centre for Epidemiology and Population Health (CESP). More information on  [https://cesp.inserm.fr/en/equipe/oncostat](https://cesp.inserm.fr/en/equipe/oncostat).

## Teaching

 + Book: Textbook of Clinical Trials in Oncology: A Statistical Perspective, 2019, CRC Press, edited by Susan Halabi & Stefan Michiels [[link]( https://www.routledge.com/Textbook-of-Clinical-Trials-in-Oncology-A-Statistical-Perspective/Halabi-Michiels/p/book/9781138083776) and [supplemental material](https://www.routledge.com/downloads/K34556/stat%20code%20book%20halabi%20michiels.zip)]
 + [R Notebooks](https://github.com/Oncostat/R_notebooks)
 + INSERM workshop 2017: predictionPenalized [[link](https://github.com/Oncostat/predictionPenalized)]


## Software

### R packages and code

+ Frequest individual patient data network meta-analysis for time-to-event data [[link](https://github.com/EdOllier/PenalizedPoissonNMA].
    
    *Described in*: Ollier E, Blanchard P, Le Teuff G, Michiels S. Penalized Poisson model for network meta-analysis of individual patient time-to-event data. Stat Med. 2021 Oct 28. doi: 10.1002/sim.9240. [[DOI](https://doi.org10.1002/sim.9240]. 

 + Biomarker selection in penalized regression models, package `biospear` [![CRAN_Status_Badge](https://www.r-pkg.org/badges/version/biospear)](https://cran.r-project.org/package=biospear) [[link](https://github.com/Oncostat/biospear)]
 
    *Described in*: Nils Ternès, Federico Rotolo, Stefan Michiels, biospear: an R package for biomarker selection in penalized Cox regression, Bioinformatics, Volume 34, Issue 1, 01 January 2018, Pages 112–113. [[DOI](https://doi.org/10.1093/bioinformatics/btx560)].

+ Evaluation of Failure Time Surrogate Endpoints in Individual Patient Data Meta-Analyses, package `surrosurv` [![CRAN_Status_Badge](https://www.r-pkg.org/badges/version/surrosurv)](https://cran.r-project.org/package=surrosurv) [[link](https://github.com/Oncostat/surrosurv)]
   
   *Described in*: Federico Rotolo, Xavier Paoletti, Stefan Michiels, surrosurv: an R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. Comput Methods Programs Biomed. 2018 Mar;155:189-198. [[DOI](https://doi.org/10.1016/j.cmpb.2017.12.005)].
   
   
 + Parametric Frailty Models, package `parfm` [![CRAN_Status_Badge](https://www.r-pkg.org/badges/version/parfm)](https://cran.r-project.org/package=parfm) [[link](https://github.com/Oncostat/parfm)]
 + Group Sequential Adaptive Designs in Series of Time-To-Event Randomised Trials in Rare Diseases: A Simulation Study [[link](https://github.com/Oncostat/Group-sequential-adaptive-designs-in-series-of-time-to-event-randomized-trials-in-rare-diseases)]
    
    *Described in*: Bayar MA, Le Teuff G, Koenig F, Le Deley MC, Michiels S. Stat Methods Med Res. 2020 Jun;29(6):1483-1498. [[DOI](https://doi.org/10.1177/0962280219862313)].
    
 + Mixed Effect Multivariate Continuation Ratio model [[link](https://github.com/Oncostat/POP1)]
    
    *Described in*: Drubay D, Collette L, Paoletti X. Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies. Contemp Clin Trials Commun. 2020 Jan 25;17:100529. [[DOI](https://doi.org/10.1016/j.conctc.2020.100529)].
    
 + Estimation of the probability of patients having a time to progression ratio superior to a given threshold [[link](https://github.com/Oncostat/TTPratio)]
    
    *Described in*: Texier M, Rotolo F, Ducreux M, Bouché O, Pignon JP, Michiels S. Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. Comput Math Methods Med. 2018 Jan 11;2018:1672176. [[DOI](https://doi.org/10.1155/2018/1672176)].
    
 + Competing risk model for meta-analysis of survival data [[link](https://github.com/AMeddis/Meta-analysis-for-competing-risk)] (collaboration with Inserm U900)
    
    *Described in*: Meddis A, Latouche A, Zhou B, Michiels S, Fine J. Meta-analysis of clinical trials with competing time-to-event endpoints. Biom J. 2020 May;62(3):712-723.  [[DOI](https://doi.org/10.1002/bimj.201900103)]. 

 
### SAS macros
 + Dual-Agent Bayesian Continual Reassessment Method [[link](https://github.com/Oncostat/CRM2dim)]
    
    *Described in*: Bayar MA, Ivanova A, Le Teuff G. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method. Comput Methods Programs Biomed. 2019 Jul;176:211-223.  [[DOI](https://doi.org/10.1016/j.cmpb.2019.04.025)]. 
   


### Online prediction models
 + Prognostic model for triple-negative breast cancer patients treated with anthracycline-based chemotherapy based on clinicopathological factors and tumour infiltrating lymphocytes [[link](https://github.com/Oncostat/PrognosTILs)]
    
    *Described in*: Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S.Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 Mar 1;37(7):559-569. [[DOI](https://doi.org/10.1200/JCO.18.01010)]. 
    
    
### Others
 + BenchmarkNCVTools [[link](https://github.com/Oncostat/BenchmarkNCVTools)]
    
    *Described in*: Drubay D, Gautheret D, Michiels S. A benchmark study of scoring methods for non-coding mutations. Bioinformatics. 2018 May 15;34(10):1635-1641. [[DOI](https://doi.org/10.1093/bioinformatics/bty008)].  

## Supplementary Material of Publication
+ Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: What methods are used in practice? Clinical Trials. 2017; 14(1):78-87 [Supplementary material (Excel table)](https://www.gustaveroussy.fr/sites/default/files/article_ct-16-0032-r1_supplementary_material.xlsx)

## Under development 

 + Drop the losers with historical control group [[link](https://github.com/Oncostat/DTLHC)]


